Inactive Instrument

Pangaea Oncology, S.A. Stock BME

Equities

ES0105221008

Biotechnology & Medical Research

Sales 2023 * 10.8M 11.58M Sales 2024 * 16.2M 17.36M Capitalization 50.35M 53.97M
Net income 2023 * - 0 Net income 2024 * - EV / Sales 2023 * 4.78 x
Net Debt 2023 * 1.3M 1.39M Net Debt 2024 * 1.9M 2.04M EV / Sales 2024 * 3.23 x
P/E ratio 2023 *
-85.5 x
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 21.08%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 06-12-31
Founder - 06-12-31
Founder - 06-12-31
Members of the board TitleAgeSince
Founder - 06-12-31
Founder - 06-12-31
Founder - 06-12-31
More insiders
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
More about the company